Trial Profile
A prospective study to evaluate long-term efficacy of Bortezomib or Lenalidomide therapy and risk adapted dosage strategies in patients with light chain (AL)amyloidosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
- 09 Dec 2015 New trial record